TLSI — TriSalus Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- $149.92m
- $145.95m
- $18.51m
Annual cashflow statement for TriSalus Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -31.8 | -28.8 | -47.2 | -59 |
| Depreciation | ||||
| Non-Cash Items | 15 | 5.82 | 12.2 | 7.55 |
| Unusual Items | ||||
| Equity in Net Earnings/Losses | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 0.892 | -0.131 | 2.3 | 0.74 |
| Change in Accounts Receivable | ||||
| Change in Inventories | ||||
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accrued Expenses | ||||
| Change in Payable / Accrued Expenses | ||||
| Cash from Operating Activities | -15.6 | -22.7 | -32.3 | -50 |
| Capital Expenditures | -0.545 | -1.1 | -0.655 | -0.588 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | -9.16 | -1.16 | -1.13 | -1.53 |
| Purchase of Investments | ||||
| Cash from Investing Activities | -9.7 | -2.26 | -1.79 | -2.12 |
| Financing Cash Flow Items | 0.019 | 0.117 | 0 | 45.4 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 24.8 | 50.8 | 13.5 | 54.6 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | -0.477 | 25.8 | -20.6 | 2.46 |